Can No­var­tis slim down CAR-T man­u­fac­tur­ing time­lines with its lat­est ac­qui­si­tion at­tempt?

No­var­tis has of­fered to buy a cell and gene ther­a­py man­u­fac­tur­er in an on­go­ing ef­fort to un­clog a com­mer­cial roll­out for its pi­o­neer­ing CAR-T ther­a­py Kym­ri­ah that’s been slowed down by man­u­fac­tur­ing woes.

Set to be­come a whol­ly owned No­var­tis fa­cil­i­ty, Cell­for­Cure first signed an agree­ment to pro­duce Kym­ri­ah in Ju­ly 2018. With the tech trans­fer com­plete, the clin­i­cal sup­ply pro­duc­tion is ex­pect­ed to be­gin by mid-2019 — when the deal is ex­pect­ed to close.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.